| Peer-Reviewed

Myelodysplastic Syndromes Experience of the Laboratory of the Military Hospital Avicenna Marrakech

Received: 31 October 2019     Accepted: 23 November 2019     Published: 13 December 2019
Views:       Downloads:
Abstract

MDS are clonal disorders of multipotent or myeloid stem cells. The disease is characterized by inefficient hematopoiesis responsible for peripheral cytopenias and contrasting with a rich marrow. The natural course of this disease is acute myeloid leukemia (AML). This is a retrospective study on the files of patients who had a haematological assessment at the laboratory of the military hospital Avicenna Marrakech between July 2014 and July 2018 for a duration of 4 years. Included in our study were all patients with documented myelodysplasia. The average age of patients is 63.63 years with extremes of 19 years and 89 years; the sex ratio was 1.3 (17 men and 13 women). NFS was abnormal in all patients, 96.66% of whom had anemia. The myelogram was performed in all patients and allowed the diagnosis of MDS in 90% of cases. Our study shows that management needs to be further improved by selecting high-risk MDS patients, potentially candidates for allogeneic hematopoietic stem cell transplantation.

Published in American Journal of Laboratory Medicine (Volume 4, Issue 6)
DOI 10.11648/j.ajlm.20190406.16
Page(s) 115-118
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2019. Published by Science Publishing Group

Keywords

Myelodysplasia, Haemogram, Anemia, Thrombocytopenia, Neutropenia-Myelogram, Genetic Mutation

References
[1] Ades L, Itzykson R, Fenaux P. Myelodysplastic syndromes. Lancet 2014; 383: 2239-52.
[2] Duchmann. M, Fenaux. P, Cluzeau. T. Prise en charge des myélodysplasies. Bull Cancer 2015; 102: 11.
[3] Heiko. K, Markus. G, Gerber. B. Syndrome myélodysplasique: physiopathologie, diagnostic et traitement. Forum Med Suisse 2013; 13 (27–28): 548–557.
[4] Fenaux. P, Ades. L. Traitement des syndromes myélodysplasiques. RFL 2009; vol 39: 77-85.
[5] Fenaux. P, Fontenay L. A. M, Raynaud. S et all. Consensus français sur les syndromes myélodysplasiques et la leucémie myélomonocytaire chronique: diagnostic, classifications, traitement. Hématologie 2015; 21: 28-45.
[6] Fontenay. M, Kosmider. O, Frisan. E, Ettou. S, Lacombe. C. physiologie des syndromes myélodysplasiques. RFL 2009; 39: 31-37.
[7] B. Odile, Guy. L, Adoue. D. Syndromes myélodysplasiques de l’adulte. Presse Med. 2007; 36: 481–91.
[8] Comont T, et al. Prise en charge des syndromes myélodysplasiques en 2019: mise au point. Rev Med Interne (2019).
[9] Roux C, Roulin L. Généralités sur les syndromes myélodysplasiques: épidémiologie, diagnostic et principes de traitement. Hématologie 2016; 22: 288-296.
[10] Bottomley SS, Fleming MD. Sideroblastic anemia: diagnosis and management. Hematol Oncol Clin North Am 2014; 28 (4): 653–70.
[11] Sheqwara J, Alkhatib Y. Sideroblastic anemia secondary to zinc toxicity. Blood 2013; 122 (3): 311.
[12] Ehsan A, Aziz M. Clinico-haematological characteristics in Pakistani patients of primary myelodysplastic syndrome according to World Health Organization classification. J Coll Physicians Surg Pak. 2010; 20 (4): 232-236.
[13] AMEL SEBAAA, VIRGINIE ECLACHE-SAUDREAU. Apport de l’hybridation in situ en fluorescence (FISH) pour la détection des anomalies cytogénétiques dans les syndromes myélodysplasiques. RFL - juin 2011.
[14] SCHANZ J, TÜCHLER H, SOLE F, ET AL. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012; 30: 820–829.
[15] BEN HASSEN, BEN YOUSSEF Y, ZAIRI M, BEN FRADI W, KHALIF A. Aspects cliniques et cytologiques des 44 cas syndromes myélodysplasiques de novo de l adulte. Tunisie 2011.
[16] MASSIMO B, MARC M, MAURO N, ET AL. Clinical features of prognostic significance in myelodysplastic patients with normal karyotype at high risk of transformation. Leukemia Research. 2005. 29: 33-39.
Cite This Article
  • APA Style

    Mouhib Hanane, Karrati Ilham, Hanane Zahir, Yahyaoui Hicham, Ait Ameur Mustapha, et al. (2019). Myelodysplastic Syndromes Experience of the Laboratory of the Military Hospital Avicenna Marrakech. American Journal of Laboratory Medicine, 4(6), 115-118. https://doi.org/10.11648/j.ajlm.20190406.16

    Copy | Download

    ACS Style

    Mouhib Hanane; Karrati Ilham; Hanane Zahir; Yahyaoui Hicham; Ait Ameur Mustapha, et al. Myelodysplastic Syndromes Experience of the Laboratory of the Military Hospital Avicenna Marrakech. Am. J. Lab. Med. 2019, 4(6), 115-118. doi: 10.11648/j.ajlm.20190406.16

    Copy | Download

    AMA Style

    Mouhib Hanane, Karrati Ilham, Hanane Zahir, Yahyaoui Hicham, Ait Ameur Mustapha, et al. Myelodysplastic Syndromes Experience of the Laboratory of the Military Hospital Avicenna Marrakech. Am J Lab Med. 2019;4(6):115-118. doi: 10.11648/j.ajlm.20190406.16

    Copy | Download

  • @article{10.11648/j.ajlm.20190406.16,
      author = {Mouhib Hanane and Karrati Ilham and Hanane Zahir and Yahyaoui Hicham and Ait Ameur Mustapha and Chakour Mohammed},
      title = {Myelodysplastic Syndromes Experience of the Laboratory of the Military Hospital Avicenna Marrakech},
      journal = {American Journal of Laboratory Medicine},
      volume = {4},
      number = {6},
      pages = {115-118},
      doi = {10.11648/j.ajlm.20190406.16},
      url = {https://doi.org/10.11648/j.ajlm.20190406.16},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajlm.20190406.16},
      abstract = {MDS are clonal disorders of multipotent or myeloid stem cells. The disease is characterized by inefficient hematopoiesis responsible for peripheral cytopenias and contrasting with a rich marrow. The natural course of this disease is acute myeloid leukemia (AML). This is a retrospective study on the files of patients who had a haematological assessment at the laboratory of the military hospital Avicenna Marrakech between July 2014 and July 2018 for a duration of 4 years. Included in our study were all patients with documented myelodysplasia. The average age of patients is 63.63 years with extremes of 19 years and 89 years; the sex ratio was 1.3 (17 men and 13 women). NFS was abnormal in all patients, 96.66% of whom had anemia. The myelogram was performed in all patients and allowed the diagnosis of MDS in 90% of cases. Our study shows that management needs to be further improved by selecting high-risk MDS patients, potentially candidates for allogeneic hematopoietic stem cell transplantation.},
     year = {2019}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Myelodysplastic Syndromes Experience of the Laboratory of the Military Hospital Avicenna Marrakech
    AU  - Mouhib Hanane
    AU  - Karrati Ilham
    AU  - Hanane Zahir
    AU  - Yahyaoui Hicham
    AU  - Ait Ameur Mustapha
    AU  - Chakour Mohammed
    Y1  - 2019/12/13
    PY  - 2019
    N1  - https://doi.org/10.11648/j.ajlm.20190406.16
    DO  - 10.11648/j.ajlm.20190406.16
    T2  - American Journal of Laboratory Medicine
    JF  - American Journal of Laboratory Medicine
    JO  - American Journal of Laboratory Medicine
    SP  - 115
    EP  - 118
    PB  - Science Publishing Group
    SN  - 2575-386X
    UR  - https://doi.org/10.11648/j.ajlm.20190406.16
    AB  - MDS are clonal disorders of multipotent or myeloid stem cells. The disease is characterized by inefficient hematopoiesis responsible for peripheral cytopenias and contrasting with a rich marrow. The natural course of this disease is acute myeloid leukemia (AML). This is a retrospective study on the files of patients who had a haematological assessment at the laboratory of the military hospital Avicenna Marrakech between July 2014 and July 2018 for a duration of 4 years. Included in our study were all patients with documented myelodysplasia. The average age of patients is 63.63 years with extremes of 19 years and 89 years; the sex ratio was 1.3 (17 men and 13 women). NFS was abnormal in all patients, 96.66% of whom had anemia. The myelogram was performed in all patients and allowed the diagnosis of MDS in 90% of cases. Our study shows that management needs to be further improved by selecting high-risk MDS patients, potentially candidates for allogeneic hematopoietic stem cell transplantation.
    VL  - 4
    IS  - 6
    ER  - 

    Copy | Download

Author Information
  • Laboratory of Hematology, Avicenna Military Hospital, Mohammed VI UHC, Marrakech, Morocco

  • Laboratory of Hematology, Avicenna Military Hospital, Mohammed VI UHC, Marrakech, Morocco

  • Laboratory of Hematology, Avicenna Military Hospital, Mohammed VI UHC, Marrakech, Morocco

  • Laboratory of Hematology, Avicenna Military Hospital, Mohammed VI UHC, Marrakech, Morocco

  • Laboratory of Hematology, Avicenna Military Hospital, Mohammed VI UHC, Marrakech, Morocco

  • Laboratory of Hematology, Avicenna Military Hospital, Mohammed VI UHC, Marrakech, Morocco

  • Sections